Noble James
Insider CIK 1388000 · MELA Director · GWPH Director · ADAP Chief Executive Officer, Director · LVTX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| LVTX LAVA Therapeutics NV | D To issuer deriv | 2025-11-13 | 2025-11-17 | 33,390 | — | $0 | 0 | SEC↗ |
| LVTX LAVA Therapeutics NV | A Award deriv | 2025-02-13 | 2025-02-18 | 33,390 | — | $0 | 33,390 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2022-07-01 | 2022-07-01 | 710,711 | — | $0 | 710,711 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2021-07-01 | 2021-07-02 | 379,788 | — | $0 | 379,788 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 17,676 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 10,740 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 16,548 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 22,464 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 34,416 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 18,636 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 9,168 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer deriv | 2021-05-05 | 2021-05-07 | 9,432 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | D To issuer | 2021-05-05 | 2021-05-07 | 27,492 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2021-02-22 | 2021-02-24 | 22,464 | — | $0 | 22,464 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2020-07-01 | 2020-07-01 | 179,785 | — | $0 | 179,785 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2020-06-04 | 2020-06-08 | 34,416 | — | $0 | 34,416 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-05-29 | 2020-06-02 | 500,000 | $9.33 | $4.67M | 0 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2020-04-01 | 2020-04-01 | 31,000 | — | $0 | 31,000 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-01-13 | 2020-01-15 | 200,000 | $5.00 | $1.00M | 0 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | S Sale | 2020-01-13 | 2020-01-15 | 100,000 | $4.00 | $400.0K | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | M Exercise deriv | 2019-05-24 | 2019-05-29 | 34,056 | — | $0 | 5 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | M Exercise deriv | 2019-05-24 | 2019-05-29 | 14,479 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | M Exercise deriv | 2019-05-24 | 2019-05-29 | 34,061 | — | $0 | 0 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | S Sale | 2019-05-24 | 2019-05-29 | 13,200 | $15.17 | $200.2K | 96,896 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | S Sale | 2019-05-24 | 2019-05-29 | 3,600 | $15.49 | $55.8K | 41,300 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | S Sale | 2019-05-24 | 2019-05-29 | 10,200 | $15.32 | $156.3K | 44,900 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | S Sale | 2019-05-24 | 2019-05-29 | 41,796 | $15.26 | $637.8K | 55,100 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | M Exercise | 2019-05-24 | 2019-05-29 | 68,117 | $4.86 | $331.0K | 110,096 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | M Exercise | 2019-05-24 | 2019-05-29 | 14,479 | — | $0 | 41,979 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | S Sale | 2019-05-24 | 2019-05-29 | 13,800 | $15.58 | $215.0K | 27,500 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | M Exercise | 2019-05-16 | 2019-05-17 | 1,773,100 | $0.14 | $248.2K | 1,773,100 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2019-03-01 | 2019-03-05 | 3,144 | — | $0 | 3,144 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2019-03-01 | 2019-03-05 | 16,548 | — | $0 | 16,548 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2019-03-01 | 2019-03-05 | 3,144 | — | $0 | 3,144 | SEC↗ |
| GWPH GW PHARMACEUTICALS PLC | A Award deriv | 2019-03-01 | 2019-03-05 | 3,144 | — | $0 | 3,144 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2019-01-04 | 2019-01-08 | 561,792 | — | $0 | 561,792 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2019-01-04 | 2019-01-08 | 2,515,536 | — | $0 | 2,515,536 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2018-01-12 | 2018-01-17 | 384,120 | — | $0 | 384,120 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2018-01-12 | 2018-01-17 | 1,719,936 | — | $0 | 1,719,936 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2017-01-13 | 2017-01-18 | 2,072,976 | — | $0 | 2,072,976 | SEC↗ |
| ADAP Adaptimmune Therapeutics P | A Award deriv | 2016-01-18 | 2016-01-20 | 1,968,016 | — | $0 | 1,968,016 | SEC↗ |
| MELA MELA SCIENCES, INC. /NY | A Award deriv | 2012-01-05 | 2012-01-06 | 10,000 | — | $0 | 10,000 | SEC↗ |